Skip to Content

Panobinostat

In the US, Panobinostat (panobinostat systemic) is a member of the drug class histone deacetylase inhibitors and is used to treat Multiple Myeloma.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XX42

CAS registry number (Chemical Abstracts Service)

0404950-80-7

Chemical Formula

C21-H23-N3-O2

Molecular Weight

349

Therapeutic Categories

Antineoplastic agent

Histone deacetylase (HDAC) inhibitor (HDI)

Chemical Name

(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide (WHO)

Foreign Names

  • Panobinostatum (Latin)
  • Panobinostat (German)
  • Panobinostat (French)
  • Panobinostato (Spanish)

Generic Names

  • Panobinostat (OS: USAN)
  • LBH589 (IS)
  • UNII-9647FM7Y3Z (IS)
  • Panobinostat Lactate (OS: JAN)
  • UNII-HN0T99OO4V (IS)

Brand Names

  • Farydak
    Novartis, United States; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharmaceuticals UK, United Kingdom

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide